Superluminal Medicines Files for IPO Following $1.3 Billion Collaboration with Eli Lilly to Develop Small Molecule Therapies for Cardiometabolic and Obesity Disorders

August 14,Boston, Massachusetts – Superluminal Medicines, a drug discovery company that integrates AI/ML, protein dynamics, and structural biology to rapidly unlock the most challenging G protein-coupled receptors (GPCRs), announced a collaboration with Eli Lilly and Company to advance novel small-molecule drugs targeting an undisclosed GPCR associated with cardiometabolic diseases and obesity. This collaboration will leverage Superluminal’s cutting-edge, structure-based drug discovery platform, combined with Eli Lilly’s expertise in small-molecule development and commercialization, to swiftly progress potential life-changing therapies.Treatment Methods. In 2023, the companyCompleted a $33 million seed funding round. In 2024, completed a $120 million Series A funding round.（New Frontier! $120 Million Series A Financing to Develop GPCR Drugs）      

Superluminal Medicines, Inc. CEO Cony D'Cruz stated:"Our collaboration with Eli Lilly and Company is a defining moment for Superluminal Medicines and a testament to the power of our platform to deliver high-quality development candidates against historically challenging GPCR targets. Our goal is to jointly develop the next generation of medicines to address the pressing and growing global cardiometabolic disease burden. We are thrilled to embark on this collaboration as we advance internal candidates targeting rare genetic forms of obesity and hypothalamic obesity, and we remain committed to bringing safe, effective, and novel therapies to patients affected by these challenging conditions."

Under the terms of the agreement with Eli Lilly and Company, Superluminal Medicines will use its proprietary platform to discover and optimize small molecule drugs targeting undisclosed GPCR targets associated with cardiometabolic diseases and obesity. After Superluminal delivers development candidates that meet predefined criteria, Eli Lilly will obtain exclusive rights to develop and commercialize the collaborative compounds. Superluminal is eligible to receive up to $1.3 billion, including upfront and near-term payments, equity investments, development and commercial milestones, as well as tiered royalties on net sales.

Superluminal’s platform integrates deep structural biology, machine learning, and proprietary pharmacokinetics and toxicology prediction tools to accelerate the discovery of small-molecule candidates. Initial efforts are focused on GPCRs, a historically challenging target class where functional selectivity and structural complexity demand next-generation computational solutions.

Superluminal Medicines, Inc. is headquartered in Boston.Eli LillyGatewayLaboratory, hasA strong investor network, including RA Capital Management, Insight Partners, NVentures (NVIDIA's venture capital arm), Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley.

Follow the official account below to see the world!